NASDAQ · SOPH

SOPHiA GENETICS SA news

$8.30−2.24%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days0English, de-duplicated

Positive0

Neutral0

Negative0

About SOPHiA GENETICS SA

No recent articles focused on SOPHiA GENETICS SA.

Also mentions SOPH

Articles that tag SOPH but are mainly about other companies.

AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players

GlobeNewswire Inc.Aug 25, 12:46 PM ET▲ Positive

Key player in AI-enabled diagnostics and genomics for blood cancer, supporting precision medicine and patient selection.

Stock Market Today: Dow Futures Tumble, S&P 500, Nasdaq Gains As Investors Await FOMC Decision— Amkor, La-Z-Boy In Focus (UPDATED)

BenzingaJun 17, 8:44 AM ET▼ Negative

Fell 3.45% in premarket after announcing a proposed public offering, which typically dilutes existing shareholder value

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology